Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 9/20 | 0.52 |
| ▸ | CNR2 | P34972 | 2/20 | 0.50 |
| ▸ | CKS1B | P61024 | 10/20 | 0.42 |
| ▸ | SKP1 | P63208 | 10/20 | 0.42 |
| ▸ | SKP2 | Q13309 | 10/20 | 0.42 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4811669 | 0.88 | CNR1 (0.42) | CNR1CNR2CKS1BSKP1SKP2 | |
| SCHEMBL5520499 | 0.83 | CNR1 (0.57) | CNR1CNR2CKS1BSKP1SKP2 | |
| SCHEMBL5530909 | 0.82 | CNR1 (0.53) | CNR1CKS1BSKP1SKP2 | |
| SCHEMBL4695724 | 0.80 | KMT2A (0.41) | CKS1BSKP1SKP2SLC6A7 | |
| SCHEMBL5516374 | 0.78 | CKS1B (0.63) | CNR1CNR2CKS1BSKP1SKP2 | |
| SCHEMBL14545542 | 0.78 | CNR1 (0.55) | CNR1CNR2CKS1BSKP1SKP2 | |
| SCHEMBL5527891 | 0.78 | SLC6A7 (0.41) | SLC6A7 | |
| SCHEMBL5515525 | 0.77 | CNR1 (0.61) | CNR1CNR2CKS1BSKP1SKP2 | |
| SCHEMBL14544995 | 0.76 | CNR1 (0.52) | CNR1CNR2 | |
| SCHEMBL14544990 | 0.75 | CNR1 (0.59) | CNR1CNR2CKS1BSKP1SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1871762-A2 | SUBTITUTED HETEROARYL CB1 ANTAGONISTS | NEUROGEN CORPORATION (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | NEUROGEN CORPORATION (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2006113704-A2 | SUBTITUTED HETEROARYL CB1 ANTAGONISTS | NEUROGEN CORPORATION (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | CNR1, CNR2, OPRL1 | CNR1 1/4885CNR2 2/4885CKS1B 1836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.